Clinical trials: T2DM
T2DM (Type 2 Diabetes Mellitus)
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone.
- Trial name
- HARMONY (NCT06415773)
- Testing
- HTD1801, Dapagliflozin
- Where
- 53 sites in China
- Volunteers
- 367 people
- Sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Type 2 Diabetes Mellitus
Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)
This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose.
- Trial name
- NCT01177384
- Testing
- Sitagliptin phosphate, Acarbose, Glimepiride
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
The study is designed to demonstrate the short term efficacy and safety of vildagliptin 50 mg bid in patients with Type 2 Diabetes Mellitus inadequately controlled with Metformin.
- Trial name
- NCT01426802
- Testing
- vildagliptin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes
IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics
This is a Phase I, first-in-human, randomised, double-blinded, placebo-and active-controlled study to assess the safety, tolerability, PK, PD, efficacy, and food-effect of IDG-16177 in healthy male subjects and patients with T2DM…
- Trial name
- NCT04982705
- Testing
- [Part 1.1] IDG-16177, [Part 2] Sitagliptin, [Part1.2] IDG-16177
- Where
- Germany
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
NASH, NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled.
- Conditions
- NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2
- Trial name
- NCT04702490
- Testing
- MET409 Active, Empagliflozin
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Metacrine, Inc.
Diabetes Type 2
Janagliflozin Treat T2DM Monotherapy
The purpose of this study is to assess the effect of Janagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 24 weeks of treatment, and to assess the efficacy after 52 weeks of treatment, overall safety and…
- Trial name
- NCT03811548
- Testing
- Janagliflozin 25mg, Janagliflozin 50mg
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Type 2 Diabetes
Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients
This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.
- Trial name
- NCT02386982
- Testing
- HMS5552
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hua Medicine Limited
Type 2 Diabetes Mellitus
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM
The purpose of the study is to compare the glycemic effects of delayed-release metformin (Met DR) to placebo in subjects with type 2 diabetes mellitus (T2DM) over 16 weeks.
- Trial name
- NCT02526524
- Testing
- Met DR, Met IR
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 571 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Type II Diabetes
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
- Trial name
- NCT00856908
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma
T2DM
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.
- Trial name
- NCT05681273
- Testing
- Chiglitazar, Empagliflozin, Atorvastatin
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes Mellitus
A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)
The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of PSN821 in patients with type 2 diabetes.
- Trial name
- NCT01386099
- Testing
- PSN821
- Where
- 4 sites in South Africa
- Volunteers
- 66 people
- Sponsor
- Prosidion Ltd.
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
T2DM (Type 2 Diabetes Mellitus)
A Study of RAY1225 in Participants With Type 2 Diabetes
The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with type 2 diabetes mellitus. The study will also explore the efficacy of RAY1225.
- Trial name
- NCT06254274
- Testing
- RAY1225
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Painful Diabetic Neuropathy, Diabetes Mellitus
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.
- Trial name
- NCT04786340
- Testing
- Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- WinSanTor, Inc
Type 2 Diabetes Mellitus
Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)
This study will examine the efficacy of omarigliptin 25 mg once weekly compared to placebo in Japanese patients with T2DM who have inadequate glycemic control on insulin monotherapy in addition to diet and exercise therapy.
- Trial name
- NCT02906709
- Testing
- Omarigliptin, Insulin
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
T2DM (Type 2 Diabetes Mellitus)
Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets
This is a pilot bioequivalence study. It is a randomized, open-label, single-dose, crossover study. The primary objective of this study is to preliminarily evaluate the pharmacokinetic parameters and their variability of the test…
- Trial name
- NCT07412015
- Testing
- treatment T (dose 1), treatment T (dose 2), treatment R (dose 1)
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Type 2 Diabetes Mellitus
Multiple-dose Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of HSK7653 in T2DM
To evaluate the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HSK7653 tablets in Type 2 Diabetes Mellitus Patients.
- Trial name
- NCT06059326
- Testing
- HSK7653 10 mg, HSK7653 25 mg, HSK7653 50 mg
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety, and tolerability of once daily oral administration of BI 10773 administered for 28 days in Japanese patients with T2DM.
- Trial name
- NCT00885118
- Testing
- BI 10773
- Where
- 5 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers
This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the pharmacokinetics and safety after co-administration of L03RD1 and L03RD2 or administration of CT-L03 in healthy volunteers.
- Trial name
- NCT07158346
- Testing
- L03RD1, L03RD2, CT-L03
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Celltrion